IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment

Completed

• Conditions: Cognitive Impairment; Insulin-like Growth Factor 1

• Registration Number: NCT02139410
• Lead Sponsor: University of Roma La Sapienza

Brief Summary

Insulin-like growth factor 1 (IGF)-1 is an important neuromyotrophic hormone. Disregulation of this hormone has been reported to influence the genesis of cognitive impairment and dementia in the elderly patients. We analyzed the possible link between IGF-1 and risk of Sarcopenia and Mortality in a cohort of elder patients with cognitive impairment.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06
• Status Verified: 2013-09
• Primary Completion: 2013-09
• Study Completion: 2013-11
• Study First Submitted: 2014-05-13
• Study First Submitted QC: 2014-05-13
• Last Update Submitted: 2014-05-13
• Study First Posted: 2014-05-15
• Last Update Posted: 2014-05-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 589

Inclusion Criteria

• Diagnosis of cognitive impairment (MMSE < 24)
• Age > 65 ys

Exclusion Criteria

• Diagnosis of pancreatic disorders
• Diagnosis of acromegaly
• Diagnosis of GH-related disorders
• Recent bone fractures or immobility before the enrollment (3 months)
• Cancer

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IGF-1 reduction in patients with sarcopenia	baseline, 24 months, 48 months	IGF-1 reduction could be linked to sarcopenia in patients with cognitive impairment

Secondary Outcome Measures

Name	Time	Method
IGF-1 reduction and mortality in patients with cognitive impairment	baseline, 24 months, 48 months	IGF-1 could be an independent risk factor for mortality in patients with cognitive impairment

Trial Locations

Locations (2)

IRCCS Galeazzi; 🇮🇹 Milan, Italy

Sapienza University of Rome; 🇮🇹 Rome, Italy